Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Acquisitions & Divestments: 2019-2024

Historic Change in Acquisitions & Divestments for Crinetics Pharmaceuticals (CRNX) over the last 6 years, with Dec 2024 value amounting to $575.8 million.

  • Crinetics Pharmaceuticals' Change in Acquisitions & Divestments rose 152.98% to $382.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 129.22%. This contributed to the annual value of $575.8 million for FY2024, which is 70.79% up from last year.
  • As of FY2024, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments stood at $575.8 million, which was up 70.79% from $337.1 million recorded in FY2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments peaked at $575.8 million during FY2024, and registered a low of $69.4 million during FY2021.
  • For the 3-year period, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments averaged around $356.8 million, with its median value being $337.1 million (2023).
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first crashed by 49.00% in 2021, then spiked by 127.08% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $136.0 million in 2020, then plummeted by 49.00% to $69.4 million in 2021, then soared by 127.08% to $157.5 million in 2022, then soared by 114.06% to $337.1 million in 2023, then skyrocketed by 70.79% to $575.8 million in 2024.